

PATIENT NAME: CHITRA GANPAT SHINGADE REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030 8800465156 ACCESSION NO: 0181XA000808

PATIENT ID : CHITF300885181

CLIENT PATIENT ID: ABHA NO : DRAWN :

AGE/SEX

Female

RECEIVED: 17/01/2024 09:23:03 REPORTED: 20/01/2024 15:03:51

:38 Years

Test Report Status <u>Final</u> Results Biological Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

XRAY-CHEST

IMPRESSION NO ABNORMALITY DETECTED

ECG

ECG WITHIN NORMAL LIMITS

MEDICAL HISTORY

RELEVANT PRESENT HISTORY HYPOTHYROID SINCE 6 YEARS

RELEVANT PAST HISTORY NOT SIGNIFICANT

RELEVANT PERSONAL HISTORY MARRIED / MIXED DIET / NO ALLERGIES / NO SMOKING / NO ALCOHOL.

MENSTRUAL HISTORY (FOR FEMALES) REGULAR 28/3 DAYS

LMP (FOR FEMALES) 08/01/2024

OBSTETRIC HISTORY (FOR FEMALES) 1 LSCS,AO,L1

RELEVANT FAMILY HISTORY FAMILY H/O THYROID DISEASE.

HISTORY OF MEDICATIONS TAB :- THYRONORM

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS1.44mtsWEIGHT IN KGS.47Kgs

BMI 23 BMI & Weight Status as follows sqmts

Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE NORMAL

Page 1 Of 28


•





View Details

View Report



Maharashtra, India





PATIENT NAME: CHITRA GANPAT SHINGADE REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138394 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030 8800465156

ACCESSION NO: 0181XA000808

PATIENT ID : CHITF300885181

CLIENT PATIENT ID: ABHA NO

AGE/SEX :38 Years

DRAWN

RECEIVED: 17/01/2024 09:23:03 REPORTED: 20/01/2024 15:03:51

Test Report Status Results Biological Reference Interval Units <u>Final</u>

PHYSICAL ATTITUDE NORMAL HEALTHY GENERAL APPEARANCE / NUTRITIONAL

STATUS AVERAGE BUILT / SKELETAL FRAMEWORK NORMAL FACIAL APPEARANCE NORMAL SKIN NORMAL **UPPER LIMB** LOWER LIMB NORMAL NECK NORMAL

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER

NOT ENLARGED THYROID GLAND CAROTID PULSATION NORMAL NORMAL TEMPERATURE

72/MIN.REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID **PULSE**

BRUIT

NORMAL RESPIRATORY RATE

CARDIOVASCULAR SYSTEM

ВР 118/80 MM HG mm/Hg

(SUPINE)

NORMAL **PERICARDIUM** NORMAL APEX BEAT NORMAL **HEART SOUNDS** ABSENT MURMURS

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST NORMAL MOVEMENTS OF CHEST SYMMETRICAL **BREATH SOUNDS INTENSITY** NORMAL

BREATH SOUNDS QUALITY VESICULAR (NORMAL)

ADDED SOUNDS ABSENT

Page 2 Of 28







Maharashtra, India





PATIENT NAME: CHITRA GANPAT SHINGADE REF. DOCTOR: SELF

CODE/NAME & ADDRESS :C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO: 0181XA000808

PATIENT ID : CHITF300885181

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX :38 Years

DRAWN :

RECEIVED: 17/01/2024 09:23:03 REPORTED: 20/01/2024 15:03:51

Test Report Status Final Results Biological Reference Interval Units

PER ABDOMEN

APPEARANCE NORMAL VENOUS PROMINENCE ABSENT

LIVER NOT PALPABLE
SPLEEN NOT PALPABLE
HERNIA ABSENT

CENTRAL NERVOUS SYSTEM

HIGHER FUNCTIONS NORMAL
CRANIAL NERVES NORMAL
CEREBELLAR FUNCTIONS NORMAL
SENSORY SYSTEM NORMAL
MOTOR SYSTEM NORMAL
REFLEXES NORMAL

MUSCULOSKELETAL SYSTEM

SPINE NORMAL JOINTS NORMAL

BASIC EYE EXAMINATION

CONJUNCTIVA NORMAL
EYELIDS NORMAL
EYE MOVEMENTS NORMAL
CORNEA NORMAL

DISTANT VISION RIGHT EYE WITHOUT WITHIN NORMAL LIMIT


GLASSES

Page 3 Of 28



View Details

View Report



Thane, 400602

Maharashtra, India Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956





PATIENT NAME: CHITRA GANPAT SHINGADE REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI NEW DELHI 110030

8800465156

ACCESSION NO: 0181XA000808

PATIENT ID : CHITF300885181

CLIENT PATIENT ID:

DRAWN

AGE/SEX :38 Years

Female

RECEIVED: 17/01/2024 09:23:03 REPORTED: 20/01/2024 15:03:51

Biological Reference Interval Test Report Status Results Units <u>Final</u>

ABHA NO

DISTANT VISION LEFT EYE WITHOUT

GLASSES

NEAR VISION RIGHT EYE WITHOUT GLASSES NEAR VISION LEFT EYE WITHOUT GLASSES

COLOUR VISION

WITHIN NORMAL LIMIT

WITHIN NORMAL LIMIT

WITHIN NORMAL LIMIT

NORMAL

SUMMARY

RELEVANT HISTORY RELEVANT GP EXAMINATION FINDINGS REMARKS / RECOMMENDATIONS

NOT SIGNIFICANT NOT SIGNIFICANT

LOW FAT, LOW CALORIE, LOW CARBOHYDRATE, HIGH FIBRE DIET. REGULAR EXERCISE. REGULAR WALK FOR 30-40 MIN DAILY.

REPEAT LIPID PROFILE, LIVER PROFILE AFTER 3 MONTHS OF DIET AND

EXERCISE.

Page 4 Of 28





Maharashtra, India





PATIENT NAME: CHITRA GANPAT SHINGADE REF. DOCTOR: SELF CODE/NAME & ADDRESS : C000138394 ACCESSION NO: 0181XA000808 AGE/SEX :38 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL DRAWN PATIENT ID : CHITF300885181 F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 17/01/2024 09:23:03 DELHÍ ABHA NO REPORTED: 20/01/2024 15:03:51 NEW DELHI 110030 8800465156

Test Report Status Results Biological Reference Interval Units <u>Final</u>

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ULTRASOUND ABDOMEN ULTRASOUND ABDOMEN NO ABNORMALITIES DETECTED

TMT OR ECHO CLINICAL PROFILE **NEGATIVE**

Interpretation(s)

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR, THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE, HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

End Of Report Please visit www.agilusdiagnostics.com for related Test Information for this accession


Page 5 Of 28











Maharashtra, India





PATIENT NAME: CHITRA GANPAT SHINGADE REF. DOCTOR: SELF CODE/NAME & ADDRESS : C000138394 ACCESSION NO: 0181XA000808 AGE/SEX :38 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : CHITF300885181 DRAWN F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 17/01/2024 09:23:03 DELHÍ ABHA NO REPORTED: 20/01/2024 15:03:51 NEW DELHI 110030 8800465156

Test Report Status <u>Final</u> Results Biological Reference Interval Units

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turn around time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062


Page 6 Of 28





View Details





Maharashtra, India





PATIENT NAME: CHITRA GANPAT SHINGADE REF. DOCTOR: SELF CODE/NAME & ADDRESS : C000138394 ACCESSION NO: 0181XA000808 AGE/SEX :38 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : CHITF300885181 DRAWN F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 17/01/2024 09:23:03 DELHI ABHA NO REPORTED :20/01/2024 15:03:51 NEW DELHI 110030 8800465156

Test Report Status Final Results Biological Reference Interval Units

	AEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECKUP BE	LOW 4UFEMALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB)	11.5 Low	12.0 - 15.0	g/dL
METHOD: SLS- HEMOGLOBIN DETECTION METHOD RED BLOOD CELL (RBC) COUNT	4.47	3.8 - 4.8	mil/µL
METHOD : HYDRODYNAMIC FOCUSING BY DC DETECTION	т.т/	3.0 - 4.0	miny pic
WHITE BLOOD CELL (WBC) COUNT	8.43	4.0 - 10.0	thou/µL
METHOD: FLUORESCENCE FLOW CYTOMETRY			
PLATELET COUNT	299	150 - 410	thou/µL
METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION			
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV)	38.1	36.0 - 46.0	%
METHOD: CUMULATIVE PULSE HEIGHT DETECTION METHOD			
MEAN CORPUSCULAR VOLUME (MCV)	85.2	83.0 - 101.0	fL
METHOD: CALCULATED FROM RBC & HCT	25.7 Low	27.0. 22.0	5.0
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED FROM THE RBC & HGB	23.7 LOW	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN	30.2 Low	31.5 - 34.5	a/dL
CONCENTRATION (MCHC)		31.3 33	9/
METHOD: CALCULATED FROM THE HGB & HCT	4.40 15 1		0/
RED CELL DISTRIBUTION WIDTH (RDW)	14.3 High	11.6 - 14.0	%
METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE MENTZER INDEX	19.1		
MEAN PLATELET VOLUME (MPV)	10.8	6.8 - 10.9	†L
METHOD : CALCULATED FROM PLATELET COUNT & PLATELET HEMA		6.6 - 10.9	1L
TEMOS FOR ESSENCE THOMAS WEEK COOKING OF A MELECTRICAL	1100141		
WDC DIFFEDENTIAL COUNT			
WBC DIFFERENTIAL COUNT			04
NEUTROPHILS	50	40 - 80	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING LYMPHOCYTES	44 High	20 - 40	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING		20 10	, 0
MONOCYTES	5	2 - 10	%

Shop

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 7 Of 28



Miew Report





PATIENT NAME: CHITRA GANPAT SHINGADE REF. DOCTOR: SELF CODE/NAME & ADDRESS : C000138394 ACCESSION NO: 0181XA000808 AGE/SEX :38 Years

ABHA NO

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030 8800465156

PATIENT ID : CHITF300885181

CLIENT PATIENT ID:

DRAWN

Female

RECEIVED: 17/01/2024 09:23:03 REPORTED: 20/01/2024 15:03:51

Test Report Status <u>Final</u>	Results	Biological Reterence	e Interval Units
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING			
EOSINOPHILS	1	1 - 6	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	_		0.0
BASOPHILS	0	0 - 1	%
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT	4.22	2.0 - 7.0	thou/µL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	1122	2.0 7.0	3.73 3, µ2
ABSOLUTE LYMPHOCYTE COUNT	3.72 High	1.0 - 3.0	thou/µL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING			
ABSOLUTE MONOCYTE COUNT	0. 4 2	0.2 - 1.0	thou/µL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING			
ABSOLUTE EOSINOPHIL COUNT	0.07	0.02 - 0.50	thou/µL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	0.00 1	0.00	M <i>I</i> I
ABSOLUTE BASOPHIL COUNT	0.00 Low	0.02 - 0.10	thou/µL
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING	4 4		
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.1		

MORPHOLOGY

RBC NORMOCYTIC NORMOCHROMIC WBC NORMAL MORPHOLOGY

METHOD: MICROSCOPIC EXAMINATION

ADEQUATE PLATELETS

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(> 13) from Beta thalassaemia trait
(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe.

3.3, COVID-19 patients tend to show mild disease.
(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr.(Mrs)Neelu K Bhojani Lab Head



Page 8 Of 28







PATIENT NAME: CHITRA GANPAT SHINGADE REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO: 0181XA000808

PATIENT ID : CHITF300885181

CLIENT PATIENT ID:

ABHA NO

AGE/SEX :38 Years

DRAWN

RECEIVED: 17/01/2024 09:23:03

REPORTED: 20/01/2024 15:03:51

Test Report Status Results Biological Reference Interval Units <u>Final</u>

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA

BLOOD

E.S.R

METHOD: MODIFIED WESTERGREN

mm

%

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE

BLOOD

HBA1C 5.6 Non-diabetic Adult < 5.7 Pre-diabetes 5.7 - 6.4

Diabetes diagnosis: > or = 6.5Therapeutic goals: < 7.0

Action suggested: > 8.0 (ADA Guideline 2021)

METHOD: HPLC

ESTIMATED AVERAGE GLUCOSE(EAG)

METHOD: CALCULATED PARAMETER

114.0

< 116.0

0 - 20

mg/dL

Interpretation(s)
ERYTHROCYTE SEDIMENTATION RATE (ESR),EDTA BLOOD-TEST DESCRIPTION:-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase In: Infections, Vasculibes, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as ibacterial endocarditis).
In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia
False Decreased: Poikilocytosis,(SickleCells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

Lab Head

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dadie and Lewis, 10th edition.

Dr.(Mrs)Neelu K Bhojani



Page 9 Of 28





PATIENT NAME: CHITRA GANPAT SHINGADE REF. DOCTOR: SELF CODE/NAME & ADDRESS : C000138394 ACCESSION NO: 0181XA000808 AGE/SEX :38 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : CHITF300885181 DRAWN F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 17/01/2024 09:23:03 DELHI ABHA NO REPORTED: 20/01/2024 15:03:51 NEW DELHI 110030 8800465156

Test Report Status Results Biological Reference Interval Units <u>Final</u>

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

1. Evaluating the indigental control of blood guices content across in diabetic patients.
2. Diagnosing diabetes.
3. Identifying patients at increased risk for diabetes (prediabetes).
The ADA recommends measurement of HbAIc (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients, to determine whether a patients metabolic control has remained continuously within the target range.
1. eAG (Estimated average glucose) converts percentage HbAIc to md/dl, to compare blood glucose levels.

- eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

- HbA1c Estimation can get affected due to:

 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

 2. Vitamin C & E are reported to talsely lower test results. (possibly by inhibiting glycation of hemoglobin.

 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction between the first processors and the interface of the consequence of
- addiction are reported to interfere with some assay methods, falsely increasing results.

 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
- c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 10 Of 28







PATIENT NAME: CHITRA GANPAT SHINGADE REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030

8800465156

ACCESSION NO: 0181XA000808

PATIENT ID : CHITF300885181

CLIENT PATIENT ID:

ABHA NO

AGE/SEX :38 Years

DRAWN

RECEIVED: 17/01/2024 09:23:03

REPORTED: 20/01/2024 15:03:51

Test Report Status Results Biological Reference Interval Units <u>Final</u>

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE O

METHOD: GEL COLUMN AGGLUTINATION METHOD.

POSITIVE RH TYPE

METHOD: GEL COLUMN AGGLUTINATION METHOD.

Interpretation(s)
ABO GROUP & RHITYPE, EDITA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of rec blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A, B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant womer are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

Dr.(Mrs)Neelu K Bhojani Lab Head



Page 11 Of 28





PATIENT NAME: CHITRA GANPAT SHINGADE REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030

8800465156

ACCESSION NO: 0181XA000808

PATIENT ID : CHITF300885181 CLIENT PATIENT ID:

ABHA NO

AGE/SEX :38 Years

DRAWN

Female

RECEIVED: 17/01/2024 09:23:03 REPORTED: 20/01/2024 15:03:51

Test Report Status Results Biological Reference Interval Units <u>Final</u>

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR)


90

Normal 75 - 99

mg/dL

Pre-diabetics: 100 - 125 Diabetic: > or = 126

METHOD: ENZYMATIC REFERENCE METHOD WITH HEXOKINASE



GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR)

METHOD: ENZYMATIC REFERENCE METHOD WITH HEXOKINASE

102

70 - 139

mg/dL


Dr. Ushma Wartikar Consultant Pathologist

Bhindhenede

Dr.Prival Chinchkhede Consultant Pathologist Dr.(Mrs)Neelu K Bhojani Lab Head



Page 12 Of 28



CIN - U74899PB1995PLC045956





PATIENT NAME: CHITRA GANPAT SHINGADE REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030 8800465156

ACCESSION NO: 0181XA000808

: CHITF300885181 PATIENT ID

CLIENT PATIENT ID: ABHA NO


AGE/SEX :38 Years

Female

DRAWN

RECEIVED: 17/01/2024 09:23:03 REPORTED: 20/01/2024 15:03:51

Test Report Status Results Biological Reference Interval Units <u>Final</u>



LIPID PROFILE WITH CALCULATED LDL

CHOLESTEROL, TOTAL 205 High Desirable: < 200 mg/dL

Borderline: 200 - 239 High: > / = 240

METHOD: ENZYMATIC COLORIMETRIC ASSAY

165 High Normal: < 150 mg/dL TRIGLYCERIDES

Borderline high: 150 - 199

High: 200 - 499 Very High: >/= 500

METHOD: ENZYMATIC COLORIMETRIC ASSAY

HDL CHOLESTEROL 42 At Risk: < 40

Desirable: > or = 60

METHOD: ENZYMATIC, COLORIMETRIC 130 High Adult levels: mg/dL CHOLESTEROL LDL

Optimal < 100

Near optimal/above optimal:

100-129

Borderline high: 130-159

High: 160-189 Very high: = 190

METHOD: ENZYMATIC COLORIMETRIC ASSAY

Dr. Ushma Wartikar Consultant Pathologist Bhindhehede

Dr.Prival Chinchkhede Consultant Pathologist

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 13 Of 28

mg/dL





PATIENT NAME: CHITRA GANPAT SHINGADE	REF. DOCTOR:	SELF
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST	ACCESSION NO: 0181XA000808 PATIENT ID: CHITF300885181 CLIENT PATIENT ID: ABHA NO:	AGE/SEX :38 Years Female DRAWN : RECEIVED :17/01/2024 09:23:03 REPORTED :20/01/2024 15:03:51

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
NON HDL CHOLESTEROL	163 High	Desirable: < 130 mg/dL
NON TIDE CHOLESTEROE	100 (1191)	Above Desirable : 130 -159 Borderline High : 160 - 189 High : 190 - 219 Very high : > / = 220
VERY LOW DENSITY LIPOPROTEIN	33.0 High	< OR = 30.0 mg/dL
CHOL/HDL RATIO	4.9 High	Low Risk: 3.3 - 4.4 Average Risk: 4.5 - 7.0 Moderate Risk: 7.1 - 11.0 High Risk: > 11.0
LDL/HDL RATIO	3.1 High	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category			
Extreme risk group	A.CAD with > 1 feature of high risk group		
-	B. CAD with > 1 feature of Very high risk g 50 mg/dl or polyvascular disease	group or recurrent ACS (within 1 year) despite LDL-C < or =	
Very High Risk		major risk factors or evidence of end organ damage 3.	
High Risk	1. Three major ASCVD risk factors. 2. Dia damage. 3. CKD stage 3B or 4. 4. LDL >1	betes with 1 major risk factor or no evidence of end organ 90 mg/dl 5. Extreme of a single risk factor. 6. Coronary otein a >/= 50mg/dl 8. Non stenotic carotid plaque	
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Ath	erosclerotic cardiovascular disease) Risk Fa	ctors	
1. Age > or 45 year	s in males and > or 55 years in females	3. Current Cigarette smoking or tobacco use	
2. Family history of p	oremature ASCVD	4. High blood pressure	
5. Low HDL			

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal < OR = 30)	<80 (Optional goal <or 60)<="" =="" td=""><td>>OR = 50</td><td>>OR = 80</td></or>	>OR = 50	>OR = 80

Dr. Ushma Wartikar Consultant Pathologist Bhindhenede.

Dr.Priyal Chinchkhede Consultant Pathologist Strajone

Dr.(Mrs)Neelu K Bhojani Lab Head

>6.0 High Risk





Page 14 Of 28

View Details







PATIENT NAME: CHITRA GANPAT SHINGADE	REF. DOCTOR:	SELF
	ACCESSION NO : 0181XA000808	AGE/SEX :38 Years Female
	PATIENT ID : CHITF300885181	DRAWN :
F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED :17/01/2024 09:23:03
NEW DELHI 110030 8800465156	ABHA NO :	REPORTED: 20/01/2024 15:03:51

Test Report Status	Einal	Results	Biological Reference Interval	Unite
rest report status	<u>rınaı</u>	Results	biological Reference frice val	OHILS

Extreme Risk Group Category B	<or 30<="" =="" th=""><th><or -="" 60<="" th=""><th>> 30</th><th>>60</th></or></th></or>	<or -="" 60<="" th=""><th>> 30</th><th>>60</th></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR 100	>OR 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

^{*}After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL METHOD: COLORIMETRIC DIAZO	0.18	Upto 1.2	mg/dL
BILIRUBIN, DIRECT METHOD: DIAZO METHOD	0.10	< 0.30	mg/dL
BILIRUBIN, INDIRECT	0.08 Low	0.1 - 1.0	mg/dL
TOTAL PROTEIN METHOD: COLORIMETRIC	7.1	6.0 - 8.0	g/dL
ALBUMIN METHOD: COLORIMETRIC	4.3	3.97 - 4.94	g/dL
GLOBULIN	2.8	2.0 - 3.5	g/dL
ALBUMIN/GLOBULIN RATIO	1.5	1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT) METHOD: UV ABSORBANCE	69 High	< OR = 35	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: UV ABSORBANCE	63 High	< OR = 35	U/L
ALKALINE PHOSPHATASE METHOD: COLORIMETRIC	77	35 - 104	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: ENZYMATIC, COLORIMETRIC	77 High	0 - 40	U/L
LACTATE DEHYDROGENASE METHOD: UV ABSORBANCE	182	125 - 220	U/L
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN METHOD: ENZYMATIC ASSAY	11	6 - 20	mg/dL

Dr. Ushma Wartikar Consultant Pathologist Bhindhenede.

Dr.Priyal Chinchkhede Consultant Pathologist Dr. (Mrs.)Naglu K. Bl

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 15 Of 28









PATIENT NAME: CHITRA GANPAT SHINGADE REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

<u>Final</u>

DELHI

NEW DELHI 110030

Test Report Status

8800465156

ACCESSION NO: 0181XA000808

PATIENT ID : CHITF300885181

CLIENT PATIENT ID: ABHA NO


Results

AGE/SEX :38 Years

DRAWN

Biological Reference Interval Units

RECEIVED: 17/01/2024 09:23:03 REPORTED :20/01/2024 15:03:51



CREATININE 0.66 0.5 - 0.9

METHOD: COLORIMETRIC

mg/dL

Dr. Ushma Wartikar Consultant Pathologist

Dr.Priyal Chinchkhede Consultant Pathologist

@hindrehede

Dr.(Mrs)Neelu K Bhojani Lab Head



Page 16 Of 28





PATIENT NAME: CHITRA GANPAT SHINGADE REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO: 0181XA000808 AGE/SEX: 38 Years Female

> : CHITF300885181 DRAWN


CLIENT PATIENT ID: ABHA NO

RECEIVED: 17/01/2024 09:23:03

REPORTED: 20/01/2024 15:03:51

Test Report Status Results Biological Reference Interval Units <u>Final</u>

PATIENT ID



BUN/CREAT RATIO		
BUN/CREAT RATIO	16.67 High	8.0 - 15.0

URIC ACID, SERUM

2.4 - 5.7mg/dL URIC ACID 2.6

METHOD: ENZYMATIC COLORIMETRIC ASSAY

TOTAL PROTEIN, SERUM

TOTAL PROTEIN 7.1 6.0 - 8.0g/dL

METHOD: COLORIMETRIC

ALBUMIN, SERUM g/dL **ALBUMIN** 4.3 3.97 - 4.94

METHOD: COLORIMETRIC

GLOBULIN

Dr. Ushma Wartikar Consultant Pathologist @hinchkhede

Dr.Priyal Chinchkhede Consultant Pathologist

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 17 Of 28



CIN - U74899PB1995PLC045956





PATIENT NAME: CHITRA GANPAT SHINGADE	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS :C000138394	ACCESSION NO: 0181XA000808	AGE/SEX :38 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST	РАПЕНТ ID : CHITF300885181	DRAWN :
DELHI	CLIENT PATIENT ID:	RECEIVED:17/01/202409:23:03
NEW DELHI 110030	ABHA NO :	REPORTED :20/01/2024 15:03:51
8800465156		

Test Report Status <u>Final</u>	Results	Biological Reference Interv	al Units		
GLOBULIN	2.8	2.0 - 3.5	g/dL		
ELECTROLYTES (NA/K/CL), SERUM					
SODIUM, SERUM	135 Low	136 - 145	mmol/L		
METHOD: ION SELECTIVE ELECTRODE TECHNOLOGY POTASSIUM, SERUM METHOD: ION SELECTIVE ELECTRODE TECHNOLOGY	4.30	3.5 - 5.1	mmol/L		
CHLORIDE, SERUM METHOD: ION SELECTIVE ELECTRODE TECHNOLOGY	101	98 - 107	mmol/L		

Interpretation(s)

Sodium	Potassium	Chloride	
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.	
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea), diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice, or al contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration, renal failure, Addison's discase, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics, NSAIDs, beta-blockers, ACE inhibitors, highdose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.	
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)	

Interpretation(s)
GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION
Normally, the glucose concentration in extracellular fluic is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in: Dilabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

Dr. Ushma Wartikar Consultant Pathologist

Dr.Priyal Chinchkhede Consultant Pathologist

Dhindhenede.

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 18 Of 28





Fax:

CIN - U74899PB1995PLC045956





PATIENT NAME: CHITRA GANPAT SHINGADE REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO: 0181XA000808

PATIENT ID : CHITF300885181

LIENT PATIENT ID:

DRAWN

ABHA NO

AGE/SEX :38 Years

RECEIVED: 17/01/2024 09:23:03

REPORTED: 20/01/2024 15:03:51

Test Report Status Results Biological Reference Interval Units <u>Final</u>

Decreased in : Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy(adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency

diseases(e.g. galactosemia), Drugs-insulin, ethanol, propranolol; sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylatec hemoglobin(HbA1c) levels are tayored to monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylatec hemoglobin(HbA1c) levels are tayored to monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylatec hemoglobin(HbA1c) levels are tayored to monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylatec hemoglobin(HbA1c) levels are tayored to monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylatec hemoglobin(HbA1c) levels are tayored to monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylatec hemoglobin(HbA1c) levels are tayored to monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylatec hemoglobin(HbA1c) levels are tayored to monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals.

index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High tasting glucose level in comparison to post prandial glucose, level may be seen due to effect of Oral Hypoglycaemics & Insulin

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c

LIVER FUNCTION PROFILE, SERUMBilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termec Gilbert syndrome, due to low levels of the enzyme that

may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Glibert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin. **AST** is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, is chemia to the liver, chronic hepatitis, postruction or bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

In Hypophosphatasia, Mainutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dystunction. Elevated serum GGT activity can be found in diseases of the liver, billiary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcoholi consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic experiences.

syndrome,Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular

permeability or decreased lymphatic clearance, malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increasec protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blooc flow, Loss of body fluic (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blooc pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Myasthenia Gravis, Muscuophy
URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapic weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic
syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis
TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.
Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic

syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, mainutrition and wasting etc.

Dr. Ushma Wartikar Consultant Pathologist

Dr.Prival Chinchkhede Consultant Pathologist

Bhinchkhede

Dr.(Mrs)Neelu K Bhojani Lab Head



Page 19 Of 28





PATIENT NAME: CHITRA GANPAT SHINGADE REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

ACCESSION NO: 0181XA000808

PATIENT ID : CHITF300885181 CLIENT PATIENT ID:

ABHA NO

AGE/SEX :38 Years

DRAWN

RECEIVED: 17/01/2024 09:23:03 REPORTED: 20/01/2024 15:03:51

Test Report Status Results Biological Reference Interval Units <u>Final</u>

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, URINE

PALE YELLOW COLOR

METHOD: MICROSCOPIC EXAMINATION

CLEAR APPEARANCE

METHOD: MICROSCOPIC EXAMINATION

CHEMICAL EXAMINATION, URINE

6.0 5.00 - 7.50

METHOD: METHYL RED & BROMOTHYMOL BLUE

1.005 Low 1.010 - 1.030 SPECIFIC GRAVITY **PROTEIN** NOT DETECTED NOT DETECTED

METHOD: TETRA BROMOPHENOL BLUE/SULFOSALICYLIC ACID

NOT DETECTED NOT DETECTED **GLUCOSE**

METHOD: GLUCOSE OXIDASE / PEROXIDASE (GOD - POD) METHOD

NOT DETECTED KETONES NOT DETECTED

METHOD: SODIUM NITROPRUSSIDE REACTION

NOT DETECTED NOT DETECTED BLOOD

METHOD: STRIP TEST - DIAZONIUM SALT COUPLING

NORMAL **NORMAL** UROBILINOGEN

METHOD: CAFFEINE BENZOATE

NOT DETECTED NOT DETECTED NITRITE

METHOD: STRIP NAPHTHOETHYLENEDIAMINE HYDROCHOLORIDE, TATTANIC ACID

LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED

METHOD: STRIP HETROCYCLIC CARBOXYLIC ACID ESTER, DIAZONIUM SALT

MICROSCOPIC EXAMINATION, URINE

/HPF **NOT DETECTED** RED BLOOD CELLS NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION /HPF PUS CELL (WBC'S) 1-2 0-5

METHOD: MICROSCOPIC EXAMINATION **EPITHELIAL CELLS** 1-2 /HPF

METHOD: MICROSCOPIC EXAMINATION

Bhindhehede

Dr.Prival Chinchkhede Consultant Pathologist Consultant Pathologist

Dr. Ushma Wartikar

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 20 Of 28





PATIENT NAME: CHITRA GANPAT SHINGADE		REF. DOCTOR:	SELF		
CODE/NAME & ADDRESS :C000138394	ACCESSION NO	: 0181XA000808	AGE/SEX	:38 Years Fer	male
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID	: CHITF300885181	DRAWN	:	
DELHI	CLIENT PATIEN	TID:	RECEIVED	:17/01/2024 09:2	23:03
NEW DELHI 110030	ABHA NO	:	REPORTED	:20/01/2024 15:0	3:51

Test Report Status Final Results Biological Reference Interval Units

NOT DETECTED

CASTS NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

CRYSTALS

METHOD: MICROSCOPIC EXAMINATION

BACTERIA NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

YEAST NOT DETECTED NOT DETECTED

Interpretation(s)

8800465156

The following table describes the probable conditions, in which the analytes are present in urine

Presence of Conditions			
Proteins	Inflammation or immune illnesses		
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment		
Glucose	Diabetes or kidney disease		
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst		
Urobilinogen	Liver disease such as hepatitis or cirrhosis		
Blood	Renal or genital disorders/trauma		
Bilirubin	Liver disease		
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases		
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination b genital secretions		
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time		
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein		
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases		
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice		

Bhindhenede.

Dr.Priyal Chinchkhede Consultant Pathologist Dr. Ushma Wartikar Consultant Pathologist

Dr.(Mrs)Neelu K Bhojani Lab Head



Page 21 Of 28









PATIENT NAME: CHITRA GANPAT SHINGADE REF. DOCTOR: SELF

CODE/NAME & ADDRESS :C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI

NEW DELHI 110030 8800465156 ACCESSION NO: 0181XA000808

РАПЕNT ID : CHITF300885181

CLIENT PATIENT ID:

AGE/SEX :3

Female

:38 Years .

RECEIVED: 17/01/2024 09:23:03 REPORTED: 20/01/2024 15:03:51

Test Report Status Final Results Biological Reference Interval Units

ABHA NO

Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis cervicitis or salningitis

Bhindhehede.

Dr.Priyal Chinchkhede Consultant Pathologist Dr. Ushma Wartikar Consultant Pathologist

Dr.(Mrs)Neelu K Bhojani Lab Head



Page 22 Of 28

View Details

View Report



Agilus Diagnostics Ltd. Mulund Goregoan Link Road Mumbai, 400078 Maharashtra, India Fax: CIN - U74899PB1995PLC045956





PATIENT NAME: CHITRA GANPAT SHINGADE REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030 8800465156

ACCESSION NO: 0181XA000808

PATIENT ID : CHITF300885181

CLIENT PATIENT ID: ABHA NO

AGE/SEX :38 Years

DRAWN

RECEIVED: 17/01/2024 09:23:03 REPORTED: 20/01/2024 15:03:51

Test Report Status Results Biological Reference Interval Units <u>Final</u>

CYTOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PAPANICOLAOU SMEAR

TEST METHOD CONVENTIONAL GYNEC CYTOLOGY

METHOD: MICROSCOPIC EXAMINATION

2-117/24 SPECIMEN TYPE

TWO UNSTAINED CERVICAL SMEARS RECEIVED

METHOD: MICROSCOPIC EXAMINATION 2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY REPORTING SYSTEM

SATISFACTORY SPECIMEN ADEQUACY

METHOD: PAP STAIN & MICROSCOPIC EXAMINATION

THE SMEARS SHOW MAINLY SUPERFICIAL SQUAMOUS CELLS, FEW **MICROSCOPY**

INTERMEDIATE SQUAMOUS CELLS IN THE BACKGROUND OF FEW

POLYMORPHS.

METHOD: PAP STAIN

INTERPRETATION / RESULT NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY

METHOD: PAP STAIN & MICROSCOPIC EXAMINATION

Comments

PLEASE NOTE PAPANICOLAU SMEAR STUDY IS A SCREENING PROCEDURE FOR CERVICAL CANCER WITH INHERENT FALSE NEGATIVE RESULTS HENCE SHOULD BE INTERPRETED WITH CAUTION. NO CYTOLOGICAL EVIDENCE OF HPV INFECTION IN THE SMEARS STUDIED. SMEARS WILL BE PRESERVED FOR 5 YEARS ONLY.



Page 23 Of 28

Dr.Prival Chinchkhede Consultant Pathologist









PATIENT NAME: CHITRA GANPAT SHINGADE REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138394

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030 8800465156

CLIENT PATIENT ID:

PATIENT ID

ABHA NO

: CHITF300885181

ACCESSION NO: 0181XA000808 AGE/SEX: 38 Years

DRAWN

Female

RECEIVED: 17/01/2024 09:23:03 REPORTED: 20/01/2024 15:03:51

Test Report Status Results Biological Reference Interval Units <u>Final</u>

CLINICAL PATH - STOOL ANALYSIS

NOT DETECTED

NOT DETECTED

NOT DETECTED

NOT DETECTED

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, STOOL

COLOUR YELLOW

METHOD: VISUAL

WELL FORMED CONSISTENCY

METHOD: VISUAL

MUCUS **ABSENT** NOT DETECTED

METHOD: VISUAL

VISIBLE BLOOD ABSENT ABSENT

METHOD: VISUAL

CHEMICAL EXAMINATION, STOOL

STOOL PH 6.0

METHOD: USING PH PAPER

OCCULT BLOOD NOT DETECTED **NOT DETECTED**

METHOD: GUAIAC METHOD

MICROSCOPIC EXAMINATION, STOOL

PUS CELLS 1-2

RED BLOOD CELLS NOT DETECTED NOT DETECTED

NOT DETECTED

NOT DETECTED

NOT DETECTED

/hpt /HPF

METHOD: MICROSCOPIC EXAMINATION CYSTS

METHOD: MICROSCOPIC EXAMINATION OVA

METHOD: MICROSCOPIC EXAMINATION

LARVAE

METHOD: MICROSCOPIC EXAMINATION

TROPHOZOITES

METHOD: MICROSCOPIC EXAMINATION

FAT **ABSENT** VEGETABLE CELLS **ABSENT**

Dr. Sheetal Sawant Consultant Microbiologist Page 24 Of 28











CIN - U74899PB1995PLC045956





PATIENT NAME: CHITRA GANPAT SHINGADE	REF. DOCTOR: SELF		
CODE/NAME & ADDRESS: C000138394 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST	ACCESSION NO: 0181XA000808 PATIENT ID: CHITF300885181	AGE/SEX :38 Years Female DRAWN :	
DELHI NEW DELHI 110030 8800465156	CLIENT PATIENT ID: ABHA NO :	RECEIVED :17/01/2024 09:23:03 REPORTED :20/01/2024 15:03:51	
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units	

CONCENTRATION METHOD

NO OVA $\,$ & CYST SEEN AFTER PERFORMING CONCENTRATION TECHNIQUE FOR STOOL SAMPLE.

Interpretation(s)

Stool routine analysis is only a screening test for disorders of gastrointentestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF	CONDITION		
Pus cells	Pus in the stool is an indication of infection		
Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as ulcerative colitis Infection of the digestive system. Stool examination for ova and parasite detects presence of parasitic infestation of gastrointestinal tract. Various forms of parasite that can be detected include cyst, trophozoite and larvae. One negative result does not rule out the possibility of parasitic infestation. Intermittent shedding of parasites warrants examinations of multiple specimens tested on consecutive days. Stool specimens for parasitic examination should be collected before initiation of antidiarrheal therapy or antiparasitic therapy. This test does not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia and Isospora species. Examination of Ova and Parasite has been carried out by direct and concentration techniques.		
Parasites			
Mucus	Mucus is a protective layer that lubricates, protects& reduces damage due to bacteria or viruses.		
Charcot-Leyden crystal Parasitic diseases.			
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.		
Frank blood	Bleeding in the rectum or colon.		
Occult blood	Occult blood indicates upper GI bleeding.		
Macrophages Macrophages in stool are an indication of infection as they are prote			
Epithelial cells Epithelial cells that normally line the body surface and internal orga in stool when there is inflammation or infection.			
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.		
рН	Normal stool pII is slightly acidic to neutral. Breast-fed babies generally havacidic stool.		

ADDITIONAL STOOL TESTS:

- Stool Culture: This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if treatment for GI infection worked.
- 2. <u>Feeal Calprotectin</u>: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) from Irritable Bowel Syndrome (IBS).

Dr. Sheetal Sawant Consultant Microbiologist





Page 25 Of 28









PATIENT NAME: CHITRA GANPAT SHINGADE	REF. DOCTOR	: SELF
CODE/NAME & ADDRESS: C000138394 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO: 0181XA000808 PATIENT ID: CLIENT PATIENT ID: ABHA NO:	AGE/SEX :38 Years Female DRAWN : RECEIVED :17/01/2024 09:23:03 REPORTED :20/01/2024 15:03:51
Test Report Status Final	Results Biologic	cal Reference Interval Units

Fecal Occult Blood Test(FOBT): This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia.

4. Clostridium Difficile Toxin Assay: This test is strongly recommended in healthcare associated bloody or waterydiarrhoea, due to overuse of broad spectrum antibiotics which alter the normal GI flora.

- Biofire (Film Array) G1 PANEL: In patients of Diarrhoea, Dysentry, Rice watery Stool, FDA approved, Biofire Film Array Test, (Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria, fungi, virus, parasite and other opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.
- 6. <u>Rota Virus Immunoassay</u>: This test is recommended in severe gastroenteritis in infants & children associated with watery diarrhoca, vomitting& abdominal cramps. Adults are also affected. It is highly contagious in nature.

Dr. Sheetal Sawant Consultant Microbiologist Page 26 Of 28





View Details





PERFORMED AT:

Fax:

CIN-U74899PB1995PLC045956





PATIENT NAME: CHITRA GANPAT SHINGADE REF. DOCTOR: SELF CODE/NAME & ADDRESS : C000138394 AGE/SEX

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030

8800465156

ACCESSION NO: 0181XA000808

PATIENT ID : CHITF300885181

CLIENT PATIENT ID:

DRAWN

:38 Years

RECEIVED: 17/01/2024 09:23:03 REPORTED: 20/01/2024 15:03:51

Test Report Status Results Biological Reference Interval Units <u>Final</u>

ABHA NO

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

THYROID PANEL, SERUM

Т3 75.5 Low Non-Pregnant Women ng/dL

80.0 - 200.0 Pregnant Women

1st Trimester: 105.0 - 230.0 2nd Trimester: 129.0 - 262.0

3rd Trimester: 135.0 - 262.0

METHOD: ELECTROCHEMILUMINESCENCE

7.51 Non-Pregnant Women µg/dL **T4**

5.10 - 14.10 Pregnant Women

1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10

3rd Trimester: 6.95 - 15.70

METHOD: ELECTROCHEMILUMINESCENCE

1.280 Non Pregnant Women μIU/mL TSH (ULTRASENSITIVE)

0.27 - 4.20

Pregnant Women (As per American Thyroid Association) 1st Trimester 0.100 - 2.500 2nd Trimester 0.200 - 3.000 3rd Trimester 0.300 - 3.000

METHOD: ELECTROCHEMILUMINESCENCE

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically

Dr. Ushma Wartikar Consultant Pathologist Dr.Prival Chinchkhede Consultant Pathologist

Bhinchkhede

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 27 Of 28



CIN - U74899PB1995PLC045956





PATIENT NAME: CHITRA GANPAT SHINGADE REF. DOCTOR: SELF CODE/NAME & ADDRESS : C000138394 ACCESSION NO: 0181XA000808 AGE/SEX :38 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL : CHITF300885181 PATIENT ID DRAWN F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED: 17/01/2024 09:23:03 DELHI ABHA NO REPORTED: 20/01/2024 15:03:51 NEW DELHI 110030 8800465156

Test Report Status <u>Final</u> Results Biological Reference Interval Units

active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSII	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3) Post Thyroidectomy (4) Post Radio-Iodine treatment
2	ITigh	Nonnal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TS11 levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist c.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3) Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4. TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

Dr. Ushma Wartikar Consultant Pathologist

Dr.Priyal Chinchkhede Consultant Pathologist

Bhinchkhede

Dr.(Mrs)Neelu K Bhojani Lab Head



Page 28 Of 28





